Drew Schwartz, M.D., Ph.D.  schwartzd@wustl.edu

Profile picture
Instructor, Infectious Diseases
Infectious Diseases

phone: (314) 454-6050


  • BS, Summa Cum Laude, Phi Beta Kappa, Hypercube Scholar, Duke University2007
  • PhD, NIH F30DK096751, Washington University School of Medicine2015
  • MD, Washington University in St. Louis2015


  • Pediatric Internship and Residency, Washington University/ St. Louis Children's Hospital2015 - 2017
  • Pediatric Infectious Disease Fellow, Washington University School of Medicine2017 - 2021

Licensure and Board Certification

  • 2018 - PresMO
  • 2018 - PresGeneral Pediatrics
  • 2021 - PresPediatric Infectious Diseases

Honors and Awards

  • North Carolina American Chemical Society Scholarship2006
  • Duke University Summer Biochemistry Fellowship2006
  • Duke University Department of Chemistry Hypercube Scholar award; Phi Beta Kappa; graduation with distinction; summa cum laude2007
  • Travel award to attend ASCI/AAP/APSA conference2011
  • ASM Student Travel Award and Outstanding Student Poster2011
  • Ruth L. Kirschstein NRSA for Individual Predoctoral MD/PhD Fellowship2012 - 2015
  • Schlesinger-Olivo Travel Award to attend 2013 American Society of Microbiology meeting2013
  • Student Travel Grant to attend 2014 American Society of Microbiology annual meeting2014
  • Oliver Langenberg Pediatric Physician-Scientist Training Program Trainee2015 - 2021
  • Washington University school of Medicine Medical School Teaching Award2017
  • Pediatric Infectious Disease Society St. Jude Children's Hospital Fellowship in Basic Research2018 - 2021
  • Student and Postdoctoral travel award to attend ASM Microbe2019
  • Washington University School of Medicine Department of Pediatrics Unsung Hero Award2020
  • Thrasher Research Fund Early Career Award2021 - Pres
  • Doris Duke Charitable Foundation Physician Scientist Fellowship2021 - Pres
  • NIH NIAID K08 1593842021 - Pres

Recent Publications view all (18)

Publication Co-Authors

  1. The resistance within: antibiotic disruption of the gut microbiome and resistome dynamics in infancy Cell Host & Microbe. 2022;30(5):675-683. doi:10.1016/j.chom.2022.03.013  PMID:35550670 
  2. Taxonomic changes in the gut microbiota are associated with cartilage damage independent of adiposity, high fat diet, and joint injury. Sci Rep. 2021;11(1):14560. PMCID:PMC8282619  PMID:34267289 
  3. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study. Genome Med. 2021;13(1):28. PMCID:PMC7888090  PMID:33593430 
  4. Improving ICI outcomes with a little help from my microbial friends. Cell Host Microbe. 2021;29(2):155-157. PMID:33571442 
  5. Endogenous Endophthalmitis Caused by Group B Streptococcus in a Healthy, Term Neonate. Retin Cases Brief Rep. 2021. PMID:33492072 
  6. Understanding the impact of antibiotic perturbation on the human microbiome. Genome Med. 2020;12(1):82. PMCID:PMC7523053  PMID:32988391 
  7. Complex interactions between the microbiome and cancer immune therapy. Crit Rev Clin Lab Sci. 2019;56(8):567-585. PMCID:PMC6776419  PMID:31526274 
  8. Comparative Genomics of Antibiotic-Resistant Uropathogens Implicates Three Routes for Recurrence of Urinary Tract Infections. mBio. 2019;10(4). PMCID:PMC6712402  PMID:31455657 
  9. Ureaplasma urealyticum pyelonephritis presenting with progressive dysuria, renal failure, and neurologic symptoms in an immunocompromised patient. Transpl Infect Dis. 2019;21(2):e13032. PMCID:PMC6542459  PMID:30472777 
  10. A mucosal imprint left by prior Escherichia coli bladder infection sensitizes to recurrent disease. Nat Microbiol. 2016;2:16196. PMCID:PMC5308540  PMID:27798558 
  11. Subinhibitory antibiotic therapy alters recurrent urinary tract infection pathogenesis through modulation of bacterial virulence and host immunity. MBio. 2015;6(2). PMCID:PMC4453531  PMID:25827417 
  12. Uropathogenic Escherichia coli superinfection enhances the severity of mouse bladder infection. PLoS Pathog. 2015;11(1):e1004599. PMCID:PMC4287616  PMID:25569799 
  13. Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. EBioMedicine. 2014;1(1):46-57. PMCID:PMC4457352  PMID:26125048 
  14. Impact of host age and parity on susceptibility to severe urinary tract infection in a murine model. PLoS One. 2014;9(5):e97798. PMCID:PMC4024022  PMID:24835885 
  15. Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation. Proc Natl Acad Sci U S A. 2013;110(39):15530-7. PMCID:PMC3785778  PMID:24003161 
  16. Immune modulation by group B Streptococcus influences host susceptibility to urinary tract infection by uropathogenic Escherichia coli. Infect Immun. 2012;80(12):4186-94. PMCID:PMC3497425  PMID:22988014 
  17. Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection. Infect Immun. 2011;79(10):4250-9. PMCID:PMC3187256  PMID:21807904 
  18. Immune activation and suppression by group B streptococcus in a murine model of urinary tract infection. Infect Immun. 2011;79(9):3588-95. PMCID:PMC3165466  PMID:21690238 
Last updated: 09/15/2022
© 2022 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130